Skip to main content
Michael Frumovitz, MD, Obstetrics & Gynecology, Houston, TX, University of Texas M.D. Anderson Cancer Center

MichaelM.FrumovitzMD

Obstetrics & Gynecology Houston, TX

Gynecologic Oncology

Physician

Dr. Frumovitz is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Frumovitz's full profile

Already have an account?

Education & Training

  • University of Texas M D Anderson Cancer Center
    University of Texas M D Anderson Cancer CenterFellowship, Gynecologic Oncology, 2001 - 2005
  • New York Presbyterian Hospital (Cornell Campus)
    New York Presbyterian Hospital (Cornell Campus)Residency, Obstetrics and Gynecology, 1997 - 2001
  • David Geffen School of Medicine at UCLA
    David Geffen School of Medicine at UCLAClass of 1997

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2021 - Present
  • AZ State Medical License
    AZ State Medical License 2023 - 2025
  • TN State Medical License
    TN State Medical License 2023 - 2025
  • WA State Medical License
    WA State Medical License 2023 - 2024
  • TX State Medical License
    TX State Medical License 2001 - 2024
  • AL State Medical License
    AL State Medical License 2023 - 2024
  • OK State Medical License
    OK State Medical License 2020 - 2024
  • American Board of Obstetrics and Gynecology Obstetrics & Gynecology
  • American Board of Obstetrics and Gynecology Gynecologic Oncology
  • Join now to see all

Awards, Honors, & Recognition

  • Regional Top Doctor Castle Connolly, 2014
  • Fellow (FACS) American College of Surgeons
  • Fellow (FACOG) American Congress of Obstetricians and Gynecologists

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Survival After Minimally Invasive vs Open Radical Hysterectomy for Early-Stage Cervical Cancer  
    Roni Nitecki, Pedro T Ramirez, Michael Frumovitz, Ana I Tergas, Alexander Melamed, JAMA Oncology
  • Phase II Evaluation of Nivolumab in the Treatment of Persistent or Recurrent Cervical Cancer (NCT02257528/NRG-GY002)  
    Alessandro D Santin, Michael Frumovitz, Natalia Buza, Samir Khleif, Elena S Ratner, Roisin E O'Cearbhaill, Michael Birrer, Gynecologic Oncology
  • Minimally Invasive Versus Abdominal Radical Hysterectomy for Cervical Cancer  
    Pedro T Ramirez, Robert L Coleman, Michael Frumovitz, The New England Journal of Medicine
  • Join now to see all

Authored Content

  • Survival After Minimally Invasive vs Open Radical Hysterectomy for Early-Stage Cervical CancerJune 2020
  • Survival After Minimally Invasive vs Open Radical Hysterectomy for Early-Stage Cervical CancerJune 2020

Press Mentions

  • Akeso Announces Launch of U.S. Investigator-Initiated Study of Cadonilimab (PD-1/CTLA-4 Bispecific Antibody)
    Akeso Announces Launch of U.S. Investigator-Initiated Study of Cadonilimab (PD-1/CTLA-4 Bispecific Antibody)December 7th, 2021
  • MD Anderson Launches Phase 2 HPV Vaccine Study
    MD Anderson Launches Phase 2 HPV Vaccine StudyDecember 8th, 2018
  • Inovio Announces Initiation of “MD Anderson’s HPV-Related Cancers Moon Shot” Phase 2 Trial in New HPV Indications
    Inovio Announces Initiation of “MD Anderson’s HPV-Related Cancers Moon Shot” Phase 2 Trial in New HPV IndicationsDecember 4th, 2018
  • Join now to see all

Professional Memberships

Hospital Affiliations